High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma.
Zimling, Zarah Glad; Santoni-Rugiu, Eric; Bech, Cecilia; Sørensen, Jens Benn.
; 35(12): 6731-8, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26637889
Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
Pathological and molecular biological approaches to early mesothelioma.
Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
<i>BAP1</i> Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.
Mesothelioma cells breaking bad: loss of integrin α7 promotes cell motility and poor clinical outcomes in patients.
Brain-derived neurotrophic factor, a new soluble biomarker for malignant pleural mesothelioma involved in angiogenesis.
Spatiotemporal Control of CNS Myelination by Oligodendrocyte Programmed Cell Death through the TFEB-PUMA Axis.
The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.